MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate

American Journal of Roentgenology

Volumn 186, Issue 2, 2006, Pages 510-515

  Warakaulle, Dinuke R ^a   Gleeson, Fergus ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

CT; Gastrointestinal imaging; Gastrointestinal stromal tumors; Imatinib mesylate; Oncologic imaging

Indexed keywords

IMATINIB; IODINATED CONTRAST MEDIUM; IOPAMIDOL; STEM CELL FACTOR RECEPTOR; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIFICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC IMAGING; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROTO ONCOGENE; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; IMAGE PROCESSING; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IOPAMIDOL; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33644989163     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.04.1516     Document Type: Article

References (11)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213-1220
2. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11:728-734
3. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226:527-532
4. Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR 2003; 180:185-189
5. Tateishi U, Hasegawa T, Satake M, Moriyama N. Gastrointestinal stromal tumor: correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr 2003; 27:792-798
6. Herman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32:578-582
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor, N Engl J Med 2001; 344:1052-1056
8. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR 2002; 179:1059-1062
9. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45:17-21
10. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004; 25:433-438
11. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT and dual-modality PET imaging for monitoring of imatinib (STI571 ) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45:357-365